Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...
Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer by licensing an early-stage candidate from Kumquat Biosciences. The deal – which has a total value of up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback